---
title: "OrganaBio: The Supply Brain | supply chain"
description: supply chain |
---

[![OrganaBio-logo-rev-white-copy](https://blog.organabio.com/hs-fs/hubfs/OrganaBio-logo-rev-white-copy.png?width=979&height=239&name=OrganaBio-logo-rev-white-copy.png "OrganaBio-logo-rev-white-copy")](https://www.organabio.com)

![brain](https://blog.organabio.com/hubfs/marketing/brain.png "brain")

# The Supply Brain

Addressing supply chain challenges in cell and gene therapy.

The OrganaBio Blog

## [You Need Access to a Robust and Reliable Donor Pool](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool)

 Posted by [Jack Camoratto](https://blog.organabio.com/en/author/jcamoratto) on June 08, 2020

- [Tweet](https://twitter.com/share)

## De-Risking the Path to Cell & Gene Therapy Commercialization Part 1: You Need Access to a Robust and Reliable Donor Pool

![Bridging the Gap from R&D to Clinical Translation](https://blog.organabio.com/hs-fs/hubfs/Imported_Blog_Media/Supply-Chain-1024x768-1.jpg?width=640&height=480&name=Supply-Chain-1024x768-1.jpg)

When [cell and gene therapy](https://www.novartis.com/our-focus/cell-and-gene-therapy/what-cell-and-gene-therapy) researchers step into the lab each morning, we envision transforming what may be an early stage experiment into a clinical success. Therapeutics developers spend years working tirelessly to generate pre-clinical data so that, when the time comes, their [Investigational New Drug (IND) application](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435682/) (or equivalent outside the USA) will be accepted by the appropriate regulatory agency, allowing the therapy to enter clinical trials. However, IND approval is just the first of [many significant hurdles](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528687/) that therapeutics developers face on the path to commercialization.

[Read More](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool)

 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool#comments-listing)

 Topics: [mesenchymal stromal cells](https://blog.organabio.com/en/tag/mesenchymal-stromal-cells), [Immune Cells](https://blog.organabio.com/en/tag/immune-cells), [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [MSCs](https://blog.organabio.com/en/tag/mscs), [Hematopoietic Stem Cells](https://blog.organabio.com/en/tag/hematopoietic-stem-cells), [donor variability](https://blog.organabio.com/en/tag/donor-variability), [Starting Materials](https://blog.organabio.com/en/tag/starting-materials-cell-gene-therapy), [supply chain](https://blog.organabio.com/en/tag/supply-chain), [OrganaBio](https://blog.organabio.com/en/tag/organabio)

[All posts](https://blog.organabio.com/en/all)

Add a Comment

### Recent Posts

### Posts by Tag

- [Allogeneic Cell Therapy (7)](https://blog.organabio.com/en/tag/allogeneic-cell-therapy)
- [Immune Cells (4)](https://blog.organabio.com/en/tag/immune-cells)
- [MSCs (4)](https://blog.organabio.com/en/tag/mscs)
- [OrganaBio (3)](https://blog.organabio.com/en/tag/organabio)
- [covid-19 (3)](https://blog.organabio.com/en/tag/covid-19)
- [Hematopoietic Stem Cells (2)](https://blog.organabio.com/en/tag/hematopoietic-stem-cells)
- [B cells (1)](https://blog.organabio.com/en/tag/b-cells)
- [Exosomes (1)](https://blog.organabio.com/en/tag/exosomes)
- [Gene Editing (1)](https://blog.organabio.com/en/tag/gene-editing)
- [Immunotherapy (1)](https://blog.organabio.com/en/tag/immunotherapy)
- [NK cells (1)](https://blog.organabio.com/en/tag/nk-cells)
- [Starting Materials (1)](https://blog.organabio.com/en/tag/starting-materials-cell-gene-therapy)
- [T cells (1)](https://blog.organabio.com/en/tag/t-cells)
- [Uncategorized (1)](https://blog.organabio.com/en/tag/uncategorized)
- [cGMP Manufacturing (1)](https://blog.organabio.com/en/tag/cgmp-manufacturing-of-cell-and-gene-therapies)
- [donor variability (1)](https://blog.organabio.com/en/tag/donor-variability)
- [iPSCs (1)](https://blog.organabio.com/en/tag/ipscs)
- [immunomodulation (1)](https://blog.organabio.com/en/tag/immunomodulation)
- [mesenchymal stromal cells (1)](https://blog.organabio.com/en/tag/mesenchymal-stromal-cells)
- [supply chain (1)](https://blog.organabio.com/en/tag/supply-chain)

See all